Cargando…
Hypercytokinemia and Pathogen–Host Interaction in COVID-19
Severe acute respiratory syndrome (SARS) coronavirus (CoV)-2 (SARS-CoV-2) is a novel coronavirus identified as the cause of coronavirus disease-2019 (COVID-19) that began in Wuhan, China in late 2019 and spread now in 210 countries and territories around the world. Many people are asymptomatic or wi...
Autor principal: | Badawi, Alaa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320995/ https://www.ncbi.nlm.nih.gov/pubmed/32606886 http://dx.doi.org/10.2147/JIR.S259096 |
Ejemplares similares
-
Hypercytokinemia in COVID-19: Tear cytokine profile in hospitalized COVID-19 patients
por: Burgos-Blasco, Barbara, et al.
Publicado: (2020) -
Continuous hemodiafiltration for hypercytokinemia in tumor lysis syndrome
por: Nakamura, M, et al.
Publicado: (2005) -
COVID-19 Severity Correlates with Weaker T-Cell Immunity, Hypercytokinemia, and Lung Epithelium Injury
por: Wang, Zhongfang, et al.
Publicado: (2020) -
The Artificial-Liver Blood-Purification System Can Effectively Improve Hypercytokinemia for COVID-19
por: Guo, Jing, et al.
Publicado: (2020) -
Current and future developments in the treatment of virus-induced hypercytokinemia
por: Wong, Jonathan P, et al.
Publicado: (2017)